Company Profile

Sedia Biosciences Corporation
Profile last edited on: 1/24/2018      CAGE: 5UEH4      UEI: LB3AM53JKK33

Business Identifier: HIV incidence assays
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

4900 Ne 122nd Avenue
Portland, OR 97230
   (503) 459-4159
Location: Single
Congr. District: 03
County: Multnomah

Public Profile

Sedia Biosciences Corporation develops HIV incidence assays, which are epidemiological tools for fighting the HIV epidemic. These products represent a laboratory assay-based approach for conducting HIV-1 surveillance, enabling the estimation of HIV-1 incidence rates. Unlike "prevalence" which is a measure of the number of infected individuals per given number of persons (i.e. a population), "Incidence" is the number of new infections per given number of persons (i.e. population) over a period of time. Classical diagnostic tests which indicate whether or not an individual is infected, can determine prevalence, but not incidence, since they do not determine if the infected individual was infected recently (i.e. a "new" infection) or was infected a long time ago (a "long-term" infection). Sedia is now adapting its platform to a variety of other infectious disease analytes, e.g. Hepatitis B SAg, Hepatitis C Ab, syphilis, etc.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2017 2 NIH $1,986,973
Project Title: Development and Commercialization of an Innovative Rapid Hiv-1 Incidence Assay
2014 2 NIH $1,194,123
Project Title: Novel Single Well Avidity Eia to Determine Recency of Hiv-1 Infections

Key People / Management

  Roger Gale -- CEO

  Ronald W Mink -- President and Chief Science Officer